Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 2.690 -0.190 (-6.60%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Lexaria Bioscience Corp < Previous 1 2 3 4 5 6 7 8 9 ... 22 23 Next > HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Human Study June 18, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study June 18, 2024 Via ACCESSWIRE Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study June 17, 2024 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide June 06, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study June 05, 2024 Via ACCESSWIRE Lexaria Awards Contract For Third GLP-1 Human Pilot Study May 23, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study June 05, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study June 05, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Product Safety Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024 May 28, 2024 Via CannabisNewsWire Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024 May 28, 2024 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study May 23, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study May 23, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, Epilepsy May 22, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy May 21, 2024 Via ACCESSWIRE CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of Dosing in Comprehensive GLP-1 Animal Study May 17, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study May 17, 2024 Via ACCESSWIRE TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Tap into Various Growing Markets May 16, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation May 14, 2024 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation May 14, 2024 Via CannabisNewsWire Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance May 09, 2024 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance May 09, 2024 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2 May 08, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2 May 08, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study May 08, 2024 Via ACCESSWIRE Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology May 07, 2024 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology May 07, 2024 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs May 06, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs May 06, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs May 06, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement May 01, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property < Previous 1 2 3 4 5 6 7 8 9 ... 22 23 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.